Potential future therapies for heart failure: Gene transfer of β-adrenergic signaling components

Coronary Artery Disease

Volumn 10, Issue 6, 1999, Pages 401-405

  Maurice, John P ^a   Koch, Walter J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Congestive heart failure; Gene therapy; adrenergic receptor kinase; adrenergic receptors

Indexed keywords

BETA ADRENERGIC RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; CONGESTIVE HEART FAILURE; GENE THERAPY; GENE TRANSFER; HEART GRAFT; HEART MUSCLE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RABBIT; RAT; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032848056     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199909000-00009     Document Type: Review

References (33)

1. Bristow MR, Ginsburg R, Minobe W, Cubicciotti R, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. New Engl J Med 1982; 307:205-211. This paper demonstrated that the myocardial β-adrenergic receptor system was defective in human CHF. β-Adrenergic receptor density and functional coupling were measured in samples taken from end-stage failing hearts at the time of explantation and it was found that β-adrenergic receptors were downregulated as much as 50% and adenylyl cyclase activities were also decreased. This was the first study demonstrating specific biochemical defects in β-adrenergic receptors in the failing human heart.
2. 1-receptor down-regulation in heart failure. Circ Res 1986; 59:297-309.
3. 1-adrenergic receptors in the failing heart. Circulation 1993; 87:454-463. This study found that β-adrenergic receptor kinase 1 mRNA and kinase activity were significantly elevated in ventricular samples of end-stage failing human hearts. This explains the functional β-adrenergic receptor uncoupling seen in CHF.
4. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmac Ther 1993; 60:405-430.
5. Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 73:913-919.
6. Inglese J, Freedman NJ, Koch WJ, Lefkowitz RJ. Structure and mechanism of the G protein-coupled receptor kinases. J Biol Chem 1993; 268:23735-23738.
7. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
8. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N Engl J Med 1996; 334:1349-1355.
9. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation 1993; 88:472-480.
10. Anzai T, Gao M, Ping P, Hammond HK. Reduced myocardial G-protein receptor kinase in pacing-induced failure after angiotensin converting enzyme inhibition [abstract]. Circulation 1996; 94:I-643.
11. Ping P, Gelzer-Bell R, Roth DA, Kiel D, Insel PA, Hammond HK. Reduced β-adrenergic receptor activation decreases G-protein expression and β-adrenergic receptor kinase activity in porcine heart. J Clin Invest 1995; 95:1271-1280.
12. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation 1998; 98;1783-1789.
13. Ping P, Anzai T, Gao M, Hammond HK. Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Am J Physiol 1997; 273:H707-H717.
14. Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Bianchi C, Homcy CJ, et al. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest 1993; 91:907-914.
15. Spinale FG, Eble DM, Mukherjee R, Johnson WS, Walker JD. Left ventricular and myocyte structure and function following chronic ventricular tachycardia in rabbits. Basic Res Cardiol 1994; 89:456-467.
16. Maurice JP, Shah A, Kypson AP, Hata J, White DC, Glower DD, et al. Molecular β-adrenergic signaling abnormalities in failing rabbit hearts after infarction. Am J Physiol 1999; (in press).
17. 2-adrenergic receptor. Science 1994; 264:582-586.
18. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science 1995; 268:1350-1353. In this study of transgenic mice, βARK1 and a peptide inhibitor of βARK1 were targeted to the myocardium. The authors demonstrated that overexpression of βARK1 could uncouple myocardial β-adrenergic receptor signaling and also attenuate cardiac functional responses to a β-agonist, while inhibition of myocardial βARK1 resulted in enhanced in-vivo performance. This study was the first to demonstrate in vivo that βARK1 could indeed desensitize β-adrenergic receptors and it also revealed that manipulation of βARK1 in the heart could have profound effects on myocardial performance.
19. Drazner MH, Peppel KC, Dyer S, Grant AO, Koch WJ, Lefkowitz RJ. Potentiation of β-adrenergic signaling by adenoviral mediated gene transfer in adult rabbit ventricular myocytes. J Clin Invest 1997; 99:288-296.
20. 2-adrenergic receptors or by a βARK1 inhibitor delivered to the cultured myocytes via adenoviral vectors.
21. Tsurumi Y, Kearney M, Chen D, Silver M, Takeshita S, Yang J, et al. Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation 1997; 96:II-382-II-388.
22. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265:781-784.
23. 2-adrenergic receptors in large arteries. J Moll Cell Cardiol 1998; 30:1037-1045.
24. Kitsis RN, Buttrick PM, McNally EM, Kaplan ML, Leinwand LA. Hormonal modulation of a gene injected into rat heart in vivo. Proc Natl Acad Sci USA 1991; 88:4138-4142.
25. Nabel EG, Gordon D, Xang ZY, Xu L, San H, Plautz GE, et al. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther 1992; 3:649-656.
26. Franz WM, Rothmann T, Frey N, Katus HA. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc Res 1997; 35:560-566.
27. Engelhardt JF, Simon RH, Yang Y, Zepeda M, Weber-Pendleton S, Grossman M, et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther 1993; 4:759-769.
28. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonezol E, Wilson JM. Cellular immunity to viral antigens limits E1 -deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91:4407-4411.
29. Li JJ, Ueno H, Pan Y, Tomita H, Yamamoto H, Kanegae Y, et al. Percutaneous transluminal gene transfer into canine myocardium in vivo by replication-defective adenovirus. Cardiovasc Res 1995; 30:97-105.
30. Barr E, Carroll J, Kalynych AM, Tripathy SK, Kozarsky K, Wilson JM, et al. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther 1994; 1:51-58.
31. Lilly RE, Peppel K, Kypson AP, Silvestry SC, Glower DD, Koch WJ, et al. Intracoronary administration of adenovirus for gene transfer into adult myocardium. Surgical Forum 1996; 47:279-281.
32. Mahaffey KW, Raya TE, Pennock GD, Morkin E, Goldman S. Left ventricular performance and remodeling in rabbits after myocardial infarction: effects of a thyroid hormone analog. Circulation 1995; 91:794-802.
33. Kypson AP, Peppel K, Akhter SA, Lilly RE, Glower DD, Lefkowitz RJ, Koch WJ. Ex vivo adenoviral-mediated gene transfer to the transplanted adult rat heart. J Thorac Cardiovasc Surg 1998; 115:623-630.